Pop-Up Vaccination Clinic in Aurora Church helps alleviate insecurities

The telegraph

A large Israeli study found that Pfizer Jab is 94 percent effective in the “real world”

The Pfizer BioNTech vaccine is 94 percent effective after the second dose. This is evident from the first major “real world” study published on the performance of the engraving. While promising data came from Israel in the past few weeks, the Clalit Institute for Research released the results of the first detailed and controlled study yesterday (Sunday), in which 1.2 million vaccinated and unvaccinated people took part. Clalit is the largest healthcare provider in the country, serving more than half of the Israeli population. The study found that the rate of symptomatic infections decreased by 94 percent and the rate of serious illnesses among those vaccinated by 92 percent, compared with 600,000 who were not vaccinated. Significantly, the vaccine was found to be effective in all age groups, including those over the age of 70 – an age group where the vaccine’s effectiveness could not be assessed in Pfizer’s original clinical trials because too few in that age group People participated. Clalit reported high vaccine efficacy of 91 to 99 percent for seven days or more after participants received a second dose of vaccine and were rated “fully vaccinated”. The researchers said they expected this to keep increasing as more data came in beyond seven days. Prof. Ran Blitzer, Director of the Clalit Research Institute, said, “It is clear that Pfizer’s corona vaccine is most effective in real life a week after the second dose, just like the second dose [original] clinical study. “In addition, the trends we identified indicate that further follow-up for weeks after the second dose significantly increases the measured effectiveness of the vaccine. In a preliminary study, we found even greater effectiveness in preventing symptomatic and serious illnesses in patients vaccinated after 14 days. “Clalit is expected to publish its full results in the next few weeks. Some also expect results to be released on how the Pfizer vaccine blocks the transmission of the virus – and rumor has it that these data are also very positive. It was difficult to verify the effectiveness of the vaccine in practice as confusing factors such as a third lockdown and a violent surge of the virus emerged in Israel. The Clalit study overcame this by carefully comparing each vaccinated individual examined with an unvaccinated individual with nearly identical circumstances. “The vaccinated group was tested against a control group of approximately 600,000 unvaccinated individuals who were carefully tailored so that each vaccinated individual was tested on a long range of indicators such as infection risk for an unvaccinated individual who was similar to them . Risk of developing serious illnesses, health status and more, ”Clalit said in a press release. “The control group was created dynamically, so people were withdrawn and moved between groups as their immunization status changed over time. “This form of calculation, which gives a complete temporal similarity with the location and personal characteristics between vaccinated and unvaccinated individuals at a given point in time, allows the effects of parallel events – such as the effects of quarantine – to be fully normalized and changed Contraindications to Vaccines ”. No data on the effectiveness of the vaccine after the first dose have been published. Most of the data that came from Israel in the past few weeks suggests that the protective effect of the shock does not really kick in until after the second dose. Last week, the BioNTech scientist behind the Pfizer vaccine warned that the gap between doses shouldn’t be longer than six weeks. Protect yourself and your family by learning more about global health security

Comments are closed.